However, the use of antibodies that cross-react with all of the splice variants has raised a major concern regarding the true identity of oncogenic splice variant of SPAG9. Nevertheless, the finding that SPAG9-JAK2 fusion gene that contains exon-26 of JLP predicts poor outcome in pediatric acute lymphoblastic leukemia patients establishes a prognostic role for JLP [16]. This evidence concerns the gene SPAG9 and acute lymphoblastic leukemia.